Registered title, quoted from ClinicalTrials.gov
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
An open trial on stomach cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07518147, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Pathologically confirmed locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma;
Inclusion criterion 5
Toxicity from prior antitumor therapy has recovered to ≤Grade 1 as defined by NCI-CTCAE v6.0;
Inclusion criterion 10
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
Inclusion criterion 9
Have radiologically evaluable lesions according to RECIST 1.1 criteria;
Inclusion criterion 8
Diagnosis of other malignancies within 3 years before the first dose;
Exclusion criterion 7
Pregnant or breastfeeding women;
Exclusion criterion 19
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07518147, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntarily sign the informed consent form and comply with protocol requirements;
- No gender restriction;
- Age: ≥18 years and ≤75 years;
- Expected survival time ≥3 months;
- Pathologically confirmed locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma;
- Patients who have failed prior first-line standard treatment, with evidence of definitive radiological progression;
- Able to provide archived or fresh tumor tissue;
- Have radiologically evaluable lesions according to RECIST 1.1 criteria;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- Toxicity from prior antitumor therapy has recovered to ≤Grade 1 as defined by NCI-CTCAE v6.0;
- No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
- Organ function levels must meet the requirements;
- Urine protein ≤1+ or <1000 mg/24 h;
- For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before starting treatment; serum pregnancy testing must exclude pregnancy, and the participant must not be breastfeeding; all enrolled trial participants and their partners must agree to use adequate highly effective contraception throughout the entire treatment period and for 7 months (women) and 4 months (men) after treatment completion, and it is recommended that additional contraceptive methods be used concurrently.
Exclusion Criteria:
- Prior anti-tumor therapy;
- Positive HER2 expression in tumor tissue;
- History of severe cardiovascular and cerebrovascular diseases;
- QT interval prolongation, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmias;
- Any thrombotic event within 6 months before randomization;
- Active autoimmune diseases and inflammatory diseases;
- Diagnosis of other malignancies within 3 years before the first dose;
- Hypertension poorly controlled with two antihypertensive drugs;
- History of interstitial lung disease (ILD) treated with hormones, etc.;
- Concurrent pulmonary diseases resulting in clinically severe respiratory impairment;
- Severe infection, etc. occurring within 4 weeks before the first use of the study drug;
- Patients with poorly controlled blood glucose;
- Patients with active central nervous system metastases;
- Patients with massive serous cavity effusion, or serous cavity effusion with symptoms, or poorly controlled serous cavity effusion;
- Imaging examinations indicating that the tumor has invaded or encased major vessels in the chest, neck, pharynx, etc.;
- Patients with a history of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any excipient component of BL-M05D1;
- Prior organ transplantation or allogeneic hematopoietic stem cell transplantation;
- Positive human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
- Pregnant or breastfeeding women;
- Esophageal or gastric varices requiring intervention within the past three months, etc.;
- History of intestinal obstruction, inflammatory bowel disease, or extensive bowel resection, etc.;
- Patients with other severe physical or laboratory abnormalities or poor compliance, etc., which may increase the risk of participating in the study, or interfere with the study results, and patients deemed unsuitable for participation in this study by the investigator.
Quoted from ClinicalTrials.gov, NCT07518147, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07518147, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.